Case of presymptomatic aceruloplasminemia treated with deferasirox

Hepatology Research

Volumn 44, Issue 12, 2014, Pages 1253-1258

  Tai, Mayumi ^a,b   Matsuhashi, Nobuo ^a   Ichii, Osamu ^a   Suzuki, Tomohiro ^a   Ejiri, Yutaka ^a   Kono, Satoshi ^c   Terada, Tatsuhiro ^c   Miyajima, Hiroaki ^c   Harada, Masaru ^b  

^a FUKUSHIMA ROSAI HOSPITAL   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aceruloplasminemia; Copper; Deferasirox; Iron

Indexed keywords

CERULOPLASMIN; DEFERASIROX; FERRITIN; HEPCIDIN; IRON;

ACERULOPLASMINEMIA; ADULT; ANEMIA; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BRAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; FERRITIN BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IRON DEPLETION; IRON METABOLISM DISORDER; LIVER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; YOUNG ADULT;

EID: 84914142421     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12292     Document Type: Article

References (25)

1. Miyajima H, Nishimura Y, Mizoguchi K et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-7.
2. Miyajima H, Kohno S, Takahashi Y et al. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999; 53: 617-9.
3. Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746-51.
4. De Domenico I, Ward DM, di Patti MC et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007; 26: 2823-31.
5. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139: 393- 408.
6. Kono S, Yoshida K, Tomosugi N et al. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta 2010; 1802: 968- 75.
7. Kaneko Y, Miyajima H, Pipemo A et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010; 45: 1163-71.
8. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998; 67: 972S-7S.
9. Loreal O, Turlin B, Pigeon C et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002; 36: 851-6.
10. Mariani R, Arosio C, Pelucchi S et al. Iron chelation therapy in aeruloplasminemia: study of a patient with a novel missense mutation. Gut 2004; 53: 756-8.
11. Miyajima H, Takahashi Y, Kamata T et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997; 41: 404-7.
12. Yonekawa M, Okabe T, Asamoto Y et al. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol 1999; 42: 157-62.
13. Tajima K, Kawanami T, Nagai R et al. Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain. Neurology 1999; 53: 619-22.
14. Yoshida K. Mutations in the ceruloplasmin gene in aeruloplasminemia. Neurol Med 2004; 61: 146-50. (In Japanese.)
15. Yoshida K, Kaneko K. Aeruloplasminemia. Neurol Med 2009; 71: 517-26. (In Japanese.)
16. Kawanami T, Kato T, Daimon M et al. Hereditary ceruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatry 1996; 61: 506-9.
17. Wada S, Kimura K, Mizuno I et al. A case of aceruloplasminemia associated with insulin-dependent diabetes mellitus, cerebellar ataxia and retinal degeneration. Folia Endocrinol 1996; 72: 543-50. (In Japanese.)
18. Daimon M. Hereditary ceruloplasmin deficiency. Nippon Rinsho 2008; 66: 563-67. (In Japanese.)
19. Tiedge M, Lortz S, Drinkgern J et al. Relation between antioxidant enzyme expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-42.
20. Fasano A, Colosimo C, Miyajima H et al. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord 2008; 23: 751-5.
21. Finkenstedt A, Wolf E, Höfner E et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 2010; 53: 1101-7.
22. Skidmore FM, Dragon V, Foster P et al. Aceruloplasminemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry 2008; 79: 467-70.
23. McNeill A, Pandolfo M, Kuhn J et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60: 200-5.
24. Suzuki Y, Yoshida K, Aburakawa Y et al. Effectiveness of oral iron chelator treatment with Deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern Med 2013; 52: 1527-30.
25. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol 2008; 88: 16-23.